Showing results (171-180 of 211) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 26, 2016
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in TaiwanShang-Yi Huang, Yuan-Bin Yu, Su-Peng Yeh, et al.
Leukemia & Lymphoma|October 6, 2022
Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC studyBurhan Ferhanoglu, Tae Min Kim, Amado Karduss, et al.
Anticancer Research|December 16, 2014
Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancerMing-Yu Lien, Liang-Chih Liu, Hwei-Chung Wang, et al.
BMJ Global Health|December 4, 2020
Weekly iron-folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in MalaysiaKaitlyn L I Samson, Su Peng Loh, Siew Siew Lee, et al.
BMJ Open|February 8, 2020
Effect of once weekly folic acid supplementation on erythrocyte folate concentrations in women to determine potential to prevent neural tube defects: a randomised controlled dose-finding trial in MalaysiaKaitlyn L I Samson, Su Peng Loh, Geok Lin Khor, et al.
Leukemia Research|January 2, 2013
Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3Po-Han Lin, Ching-Chan Lin, Hwai-I Yang, et al.
Scientific Reports|September 14, 2017
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia PatientsHui-Jen Tsai, Shih Sheng Jiang, Wen-Chun Hung, et al.
EMBO Molecular Medicine|March 26, 2013
Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic strokeYung-Luen Yu, Ruey-Hwang Chou, Woei-Cherng Shyu, et al.
Blood Advances|July 24, 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AMLPau Montesinos, Dylan M Marchione, Christian Récher, et al.
Pageof 22